Clik here to view.
Merck, Seattle Genetics form partnerships worth $4.5B focused on two cancer...
One deal is a $4.2 billion development and commercialization partnership focused on ladiratuzumab vedotin, while the other would expand the reach of the breast cancer drug Tukysa.
View ArticleClik here to view.
Trial results add to uses for Exact Sciences test
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the...
View ArticleClik here to view.
FDA rejects Athenex’s oral chemotherapy, asks for another clinical trial
Athenex’s bid to offer an oral version of an intravenous chemotherapy has stalled after the FDA rejected the drug. Among the remedies proposed by the regulator is another Phase 3 study.
View ArticleClik here to view.
ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more
The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger...
View ArticleClik here to view.
Shining a light on gaps in breast cancer care: A call for increased equity
As an industry, we should be proud of all that we have accomplished in making precision medicine a reality, whether it has been through advances in screening, drug development, diagnostics, or...
View ArticleClik here to view.
Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1...
View ArticleClik here to view.
Debunking 4 myths about cancer clinical trials: The unsung hero of breast...
Clinical trials are the safest and most trusted route for identifying new breast cancer treatments, and the more research that can be done, the closer we will be to eradicating breast cancer for good.
View ArticleClik here to view.
Evidence lacking for AI-based breast cancer screening
A review of 12 studies about AI systems used to screen patients for breast cancer found that they lacked evidence to prove that they would work well in a clinical setting. Researchers highlighted...
View ArticleClik here to view.
When it comes to breast cancer, the right data & outreach strategy impacts lives
As health systems play catch up with backlogged – and potentially life-saving – screenings, it’s important they prioritize people at higher risk, to ensure they have access to the preventive care they...
View ArticleClik here to view.
Predicting therapeutic outcomes in breast cancer patients: AI’s next big task
There is a need for sophisticated and accurate forecasting software tools that incorporate precision cancer care. Technology and artificial intelligence, in particular, have the potential to improve...
View ArticleClik here to view.
Roche breast cancer drug fails in Phase 2 following similar stumble by rival...
Experimental Roche drug giredestrant failed to meet the main goal of a Phase 2 study in advanced breast cancer. The disappointing results allow competitors to gain ground in the field of companies...
View ArticleClik here to view.
Cancer biotech Pheast unveils $76M to expand immunotherapy’s menu to new targets
Biotech startup Pheast Therapeutics is out of stealth taking a tack similar to that of cancer immunotherapy company Forty Seven, also a spinout from the Stanford University lab of Irving Weissman....
View ArticleClik here to view.
INVEST Pitch Perfect winner: Athelo helps patients navigate cancer journey
Athelo Health’s software is a personal coach that supports women with breast and gynecological cancers. The startup was judged co-winner in the pharmatech category during the recent MedCity INVEST...
View ArticleClik here to view.
FDA clears wearable 3D ultrasound for breast imaging
Startup iSono Health said its FDA-cleared automated imaging system will make personalized whole breast imaging more accessible to women worldwide and could help improve breast cancer diagnosis.
View ArticleClik here to view.
Gilead offers more detail on breast cancer drug’s trial results. Is it enough?
Gilead Sciences has more detail about breast cancer drug Trodelvy, a blockbuster hopeful it acquired two years ago. Additional data from a pivotal study were presented during the annual meeting of the...
View ArticleClik here to view.
AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast...
During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a...
View ArticleClik here to view.
FDA approval of AstraZeneca drug is first for a new group of breast cancer...
Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused therapy...
View ArticleClik here to view.
Gilead claims breast cancer trial win but offers few details; drug...
Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type of breast cancer. While detailed data...
View ArticleClik here to view.
Sanofi drops out of competitive breast cancer drug race after another trial...
Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule. The move means Sanofi is...
View ArticleClik here to view.
Owkin’s AI solutions for breast and colorectal cancer receive European approval
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match...
View Article
